StockMarketWire.com - Indivior said Wednesday it had launched an authorized generic version of its opioid addiction treatment in the United States in an effort to counter the impact expected from the launch of a copycat products by its rivals.

'This business decision is based on the market impact expected from the anticipated at risk launch of a generic buprenorphine and naloxone sublingual film product in the U.S. by Dr. Reddy's Laboratories and/or Alvogen.'

The decision comes as the Supreme Court of the United States on Tuesday had denied Indivior's appeal to keep in place a preliminary injunction granted against rival Dr. Reddy's Laboratories that prevented it from selling a generic version of the company's opioid addiction treatment.


At 8:04am: [LON:INDV] Indivior Plc share price was +2.33p at 107.13p



Story provided by StockMarketWire.com